WO2025003929 - SARS-COV-2 RNA VACCINES AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2025/003929
Publication Date
02.01.2025
International Application No.
PCT/IB2024/056241
International Filing Date
27.06.2024
Title **
[English]
SARS-COV-2 RNA VACCINES AND USES THEREOF
[French]
VACCINS À ARN CONTRE LE SARS-COV-2 ET LEURS UTILISATIONS
Applicants **
SEQIRUS INC.
475 Green Oaks Parkway
Holly Springs, North Carolina 27540, US
Inventors
CHANG, Cheng
c/ Seqirus Inc.
475 Green Oaks Parkway
Holly Springs, North Carolina 27540, US
CAI, Yongfei
c/ Seqirus Inc.
475 Green Oaks Parkway
Holly Springs, North Carolina 27540, US
Priority Data
63/511,340
30.06.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 3513 | |
| EPO | Filing, Examination | 36524 | |
| Japan | Filing | 593 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 24130 |
Total: 65335 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure relates to SARS-CoV-2 RNA vaccines and uses thereof. The present disclosure also relates to conventional mRNA vaccines and self-replicating RNA vaccines for the treatment of a SARS-CoV-2 infection or COVID-19.[French]
La présente divulgation concerne des vaccins à ARN contre le SARS-CoV-2 et leurs utilisations. La présente divulgation concerne également des vaccins à ARNm classiques et des vaccins à ARN à autoréplication pour le traitement d'une infection par le SARS-CoV-2 ou de la COVID-19.